Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression

Fondazione Italiana Linfomi - ETS175 enrolled

Overview

The study is designed as a retrospective analysis of patients with relapsed/refractory FL identified by the hematological centers of Italy.

The study does not require any intervention on the patient, but it involves the simple collection of data that are already present in the medical record. Since this is a retrospective study, it will not require further analysis or diagnostic investigations than those already made.

Study Type

OBSERVATIONAL

Enrollment

175

Conditions

Follicular Lymphoma

Interventions

Metabolic activity measured by FDG-PETOTHER

To evaluate whether metabolic activity measured by FDG-PET (SUV max) at time of relapse is predictive of patient's outcome.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with initial diagnosis of follicular lymphoma since 2001 * Histological confirmation of follicular lymphoma, grade I, II, III according to WHO 2008 classification, at the time of initial diagnosis * Systemic first-line treatment with immuno-chemotherapy * PET availability at the time of response after first-line treatment (optional) * Clinical and radiological evidence of FL relapse or progression * Histological confirmation of relapse (strongly recommended) * PET availability of at the time of relapse/progression and images available for central assessment * Availability of clinical, laboratory and therapeutic treatment data at the time of initial diagnosis and relapse/progression * Follow up of at least 12 months after relapse/progression Exclusion Criteria: * None

Locations (27)

Outcomes

Primary Outcomes

PFS

Progression free survival from time of relapse/progression

Time frame: 24 months

Secondary Outcomes

Overall survival

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.